

![]() |
Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer's Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial |
|
Authors | ![]() | |
Published in | Journal of Alzheimer's Disease. 2018, vol. 61, no. 1, p. 435-457 | |
Abstract | LMTM is being developed as a treatment for AD based on inhibition of tau aggregation. | |
Keywords | Aged — Aged, 80 and over — Alzheimer Disease/diagnostic imaging/drug therapy — Antipsychotic Agents/therapeutic use — Cohort Studies — Double-Blind Method — Female — Humans — International Cooperation — Male — Mental Status and Dementia Tests — Methylene Blue/analogs & derivatives/therapeutic use — Middle Aged — Treatment Outcome | |
Identifiers | DOI: 10.3233/JAD-170560 PMID: 29154277 | |
Full text | ||
Structures | ||
Research group | Troubles de mémoire et maladie d'Alzeimer (935) | |
Citation (ISO format) | WILCOCK, Gordon K et al. Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer's Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial. In: Journal of Alzheimer's Disease, 2018, vol. 61, n° 1, p. 435-457. doi: 10.3233/JAD-170560 https://archive-ouverte.unige.ch/unige:116075 |